Alphatec Spine to Showcase New Products at the Upcoming 27th Annual North American Spine Society (NASS) Meeting in Dallas, Texa
23 Octobre 2012 - 1:35PM
Alphatec Holdings, Inc. (Nasdaq:ATEC), the parent company of
Alphatec Spine, Inc., a medical device company that designs,
develops, manufactures and markets products for the surgical
treatment of spine disorders, with a focus on treating conditions
related to the aging spine, announced today that it will showcase
several new products at the upcoming North American Spine Society
(NASS) meeting in Dallas, TX, which will be held from October 24th
to 26th, 2012. Alphatec Spine will be located in booth number 1116.
This year's product showcase will include:
Trestle LuxeTM Anterior Cervical Plating System
is the Company's next-generation anterior cervical fixation system.
Trestle Luxe is a unique and easy to use system that incorporates a
zero-step locking mechanism into one of the lowest profile plates
available. Trestle Luxe incorporates a number of other beneficial
features such as large windows that enable better graft site/end
plate visualization, an assortment of screws that provide multiple
fixation options, plus a comprehensive array of implants and
instrumentation to meet surgeon needs.
BridgePoint™ Spinous Process Fixation System is
Alphatec Spine's newest Minimally Invasive Surgery (MIS) device
that is designed to enable spine surgeons to immobilize and
stabilize spinal segments without the need for pedicle screw and
rod constructs. The BridgePoint System is intended to be an adjunct
to fusion of the thoracic and lumbar spine to treat disorders
resulting from degenerative disc disease, spondylolisthesis, tumor
and trauma. The device's state of the art design incorporates
unique telescoping plates that allow users to compress the anterior
column for a reliable interbody fusion, and its large bone contact
area provides a strong anchor point from which to apply compression
as well as optimal stability during the fusion process.
Alphatec NEXoss™, is a next-generation
synthetic bone graft indicated for use in posterolateral spine
fusions in conjunction with bone marrow aspirate, autograft bone
and appropriate hardware. Alphatec NEXoss is composed of two unique
patented technologies. The first is an engineered extracellular
collagen bioscaffold that provides a physical structure for cell
infiltration and attachment. The second is osteoconductive
nano-structured bone crystals that have similar composition,
structure and size as human bone. These two technologies function
together to provide an ideal environment for a natural bone growth
solution. Alphatec NEXoss is supported by in vitro and in vivo
clinical data.
"We are pleased to highlight our newest products, as well as the
entire Alphatec Spine product portfolio, at the 27th annual NASS
meeting this month. We also look forward to meeting many surgeons,
investors and analysts at NASS," said Les Cross, Chairman and Chief
Executive Officer of Alphatec Spine. "Each new product represents
the latest in our technology and provides unique benefits that
deliver real value to surgeons, hospitals and patients. Our
strategy is to deliver a continuous stream of new products that are
focused on minimally invasive techniques and Biologics solutions
into an expanding geographical footprint. We are proud to play a
role in helping patients who suffer from spinal disorders and
chronic pain, regain their active lifestyles."
In addition, on Thursday, October 25 at 10:00 am in Hall B,
Alphatec Spine will participate in the NASS Solution Showcase and
will present "Introducing Trestle Luxe Anterior Cervical Plating
and Initial Clinical Experience". The Company will also offer
interactive Sawbones Workshops at its booth (booth #1116) during
exhibit hours.
About Alphatec Spine
Alphatec Spine, Inc. is a wholly owned subsidiary of Alphatec
Holdings, Inc. (Nasdaq:ATEC). Alphatec Spine is a medical device
company that designs, develops, manufactures and markets products
for the surgical treatment of spine disorders, primarily focused on
the aging spine. The Company's mission is to combine world-class
customer service with innovative, surgeon-driven products that will
help improve the aging patient's quality of life. The Company is
poised to achieve its goal through new solutions for patients with
osteoporosis, stenosis and other aging spine deformities, improved
minimally invasive products and techniques and integrated biologics
solutions. In addition to its U.S. operations, the Company
also markets its products in over 50 international markets through
its affiliate, Scient'x S.A.S., via a direct sales force in France,
Italy and the United Kingdom and via independent distributors in
the rest of Europe, the Middle East and Africa. In Latin America,
the Company conducts its business through its subsidiary, Cibramed
Produtos Medicos. In Japan, the Company markets its products
through its subsidiary, Alphatec Pacific, Inc. In the rest of
Asia and Australia, the Company sells its and Scient'x's products
through its and Scient'x's distributors.
The Alphatec Holdings, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=3520
Forward Looking Statements
This press release may contain "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995 that involve risks and uncertainty. Such statements are
based on management's current expectations and are subject to a
number of risks and uncertainties that could cause actual results
to differ materially from those described in the forward-looking
statements. Alphatec Spine cautions investors that there can be no
assurance that actual results or business conditions will not
differ materially from those projected or suggested in such
forward-looking statements as a result of various factors.
Forward-looking statements include references to the Company's
belief that certain of its products offer competitive
functionalities in the marketplace. In addition, forward-looking
statements include the Company's ability to develop and
commercialize new products in MIS. The words "believe," "will,"
"should," "expect," "intend," "estimate" and "anticipate,"
variations of such words and similar expressions identify
forward-looking statements, but their absence does not mean that a
statement is not a forward-looking statement. The important
factors that could cause actual operating results to differ
significantly from those expressed or implied by such
forward-looking statements include, but are not limited to; the
uncertainty of success in developing or acquiring and
commercializing new products or product technologies; acceptance of
Alphatec Spine's products by the surgeon community; failure to
successfully implement streamlining activities to create operating
cost savings; failure to successfully begin in-house manufacturing
of certain products; failure to obtain or maintain FDA clearance or
approval for new products or technologies, including the product
discussed in this press release, or unexpected or prolonged delays
in the process; Alphatec Spine's ability to develop and expand its
U.S. and/or global revenues; continuation of favorable third part
payor reimbursement for procedures performed using Alphatec Spine's
products; unanticipated expenses or liabilities or other adverse
events affecting cash flow or Alphatec Spine's ability to
successfully control its costs or achieve profitability;
uncertainty of additional funding; Alphatec Spine's ability to
compete with other competing products and with emerging new
technologies; product liability exposure; failure to meet all
financial obligations in the Cross Medical Settlement; patent
infringement claims and claims related to Alphatec Spine's
intellectual property. Please refer to the risks detailed from time
to time in Alphatec Spine's SEC reports, including its Annual
Report Form 10-K, as well as other filings on Form 10-Q and
periodic filings on Form 8-K. Alphatec Spine disclaims any
intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events,
or otherwise, unless required by law.
CONTACT: Investor/Media Contact:
Mark Francois
Senior Director, Investor Relations
Alphatec Spine, Inc.
(760) 494-6610
mfrancois@alphatecspine.com
Alphatec (NASDAQ:ATEC)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Alphatec (NASDAQ:ATEC)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024